Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations: Difference between revisions
| [unchecked revision] | [unchecked revision] |
added intro and legend |
adding gene links, partially complete |
||
| Line 12: | Line 12: | ||
|1p32 | |1p32 | ||
|Loss | |Loss | ||
|''FAF1, CDKN2C'' | |''[[FAF1]], [[CDKN2C]]'' | ||
|Poor prognostic marker | |Poor prognostic marker | ||
|1, 2 | |1, 2 | ||
| Line 19: | Line 19: | ||
|1p22.2-p22.1 | |1p22.2-p22.1 | ||
|Loss | |Loss | ||
|''BARHL2, TGFBR3, and others; HSP90B3P, TGFER3, BRDT, EPHAX4, BTBD8'' | |''[[BARHL2]], [[TGFBR3]], and others; [[HSP90B3P]], [[TGFER3]], [[BRDT]], [[EPHAX4]], [[BTBD8]]'' | ||
|Prognostic | |Prognostic | ||
|1, 3 | |1, 3 | ||
| Line 26: | Line 26: | ||
|1p21.3 | |1p21.3 | ||
|Loss | |Loss | ||
|''SNX7'' | |''[[SNX7]]'' | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| Line 40: | Line 40: | ||
|1p12 | |1p12 | ||
|Loss | |Loss | ||
|''MAN1A2, FAM46C, GDAP2'' | |''[[MAN1A2]], [[FAM46C]], [[GDAP2]]'' | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| Line 61: | Line 61: | ||
|1q21.2-q23 | |1q21.2-q23 | ||
|Gain | |Gain | ||
|''CKS1B'' and ''ANP32E'' | |''[[CKS1B]]'' and ''[[ANP32E]]'' | ||
|Recurrent | |Recurrent | ||
|1 | |1 | ||
| Line 106: | Line 106: | ||
|4p16.3 | |4p16.3 | ||
|Loss | |Loss | ||
|''FGFR3'' and ''WHSC1'' | |''[[FGFR3]]'' and ''[[WHSC1]]'' | ||
|Recurrent | |Recurrent | ||
|3 | |3 | ||
| Line 113: | Line 113: | ||
|4p15.2 | |4p15.2 | ||
|Loss | |Loss | ||
|''LGI2, SEPSECS, PI4K2B'' and others | |''[[LGI2]], [[SEPSECS]], [[PI4K2B]]'' and others | ||
|Recurrent | |Recurrent | ||
|3 | |3 | ||
| Line 120: | Line 120: | ||
|4q35.1 | |4q35.1 | ||
|Loss | |Loss | ||
|''DCTD, ING2,'' and others | |''[[DCTD]], [[ING2]],'' and others | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| Line 163: | Line 163: | ||
|5q13.2 | |5q13.2 | ||
|Loss | |Loss | ||
|''OCLN, NAIP'', and others | |''[[OCLN]], [[NAIP]]'', and others | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| Line 192: | Line 192: | ||
|6q11.1-q13 | |6q11.1-q13 | ||
|Gain | |Gain | ||
|''MTRNR2L9'' | |''[[MTRNR2L9]]'' | ||
|Recurrent | |Recurrent | ||
|3 | |3 | ||
| Line 199: | Line 199: | ||
|6q16.3 | |6q16.3 | ||
|Loss | |Loss | ||
|''COQR, GRIK2'' | |''[[COQR]], [[GRIK2]]'' | ||
|Recurrent | |Recurrent | ||
|3 | |3 | ||
| Line 206: | Line 206: | ||
|6q25.3 | |6q25.3 | ||
|Loss | |Loss | ||
|''IGFR3'' | |''[[IGFR3]]'' | ||
|Recurrent | |Recurrent | ||
|3 | |3 | ||
| Line 235: | Line 235: | ||
|7p15.2 | |7p15.2 | ||
|Gain | |Gain | ||
|''CBX3, etc'' | |''[[CBX3]], etc'' | ||
|Recurrent | |Recurrent | ||
|3 | |3 | ||
| Line 257: | Line 257: | ||
|8p23.1 | |8p23.1 | ||
|Loss | |Loss | ||
|''DEFB4'' and others | |''[[DEFB4]]'' and others | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| Line 264: | Line 264: | ||
|8p21.3/p21.2 | |8p21.3/p21.2 | ||
|Loss | |Loss | ||
|''TNFRSF10B, DOCK5'' and others | |''[[TNFRSF10B]], [[DOCK5]]'' and others | ||
|Recurrent | |Recurrent | ||
|3 | |3 | ||
| Line 278: | Line 278: | ||
|8q24.2 | |8q24.2 | ||
|Gain/amplification and Loss | |Gain/amplification and Loss | ||
|''MYC'' | |''[[MYC]]'' | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| Line 714: | Line 714: | ||
Level 2: emerging evidence (by one large study or multiple case reports) | Level 2: emerging evidence (by one large study or multiple case reports) | ||
Level 3: presumptive evidence (multiple case reports or expert opinion)<references /> | Level 3: presumptive evidence (multiple case reports or expert opinion) | ||
==Reference== | |||
<references /> | |||